Related Experiment Video
Updated: Aug 8, 2026
Novel Diagnostics in Revision Arthroplasty: Implant Sonication and Multiplex Polymerase Chain Reaction
Published on: December 3, 2017
Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series
1University of Pittsburgh School of Medicine, Department of Medicine, Division of Infectious Disease, Pittsburgh, PA, USA. raon@upmc.edu
Abstract:
Daptomycin is an option for prosthetic joint infection (PJI) because it is bactericidal against gram-positive bacteria, including multiple-resistant isolates, and active against stationary-phase bacteria in biofilm present on implants. To evaluate its possible utility, we prospectively monitored 12 adults with gram-positive PJI who were not candidates for vancomycin. Pathogens included methicillin-resistant Staphylococcus aureus (n = 7), methicillin-resistant-coagulase-negative Staphylococci (n = 4), and methicillin-sensitive Staphylococcus aureus (n = 1). All patients completed a 6-week course of daptomycin 4 mg/kg/day. One died of an unrelated cause shortly after completing therapy. After a followup of 7 to 13 months, six patients had no clinical, laboratory, or radio-graphic signs of recurrence. One patient failed a first course and was subsequently treated with hardware removal and a second course with no recurrence. Five patients had culture-confirmed failure-all due to MRSA-including two during therapy despite hardware removal and three 1 to 10 months after completing daptomycin but with retained hardware. The efficacy of daptomycin 4 mg/kg/day is uncertain in patients with PJI, especially when hardware is retained. Further study is needed to determine why in vitro data did not predict clinical success and to ascertain any potential benefit from higher doses.
Insights
Daptomycin showed uncertain efficacy for prosthetic joint infections (PJI) in a small study. Higher doses or retained hardware may impact treatment success for Gram-positive bacterial infections.
Area of Science:
- Infectious Diseases
- Orthopedic Surgery
- Pharmacology
Background:
- Prosthetic joint infection (PJI) poses a significant challenge due to biofilm formation on implants.
- Daptomycin exhibits bactericidal activity against Gram-positive bacteria, including resistant strains and those in biofilms.
- Limited treatment options exist for patients with PJI who cannot receive vancomycin.
Purpose of the Study:
- To prospectively evaluate the clinical utility of daptomycin in adult patients with Gram-positive PJI.
- To assess treatment outcomes in patients ineligible for vancomycin therapy.
Main Methods:
- A prospective study of 12 adult patients with Gram-positive PJI.
- Patients received a 6-week course of daptomycin at 4 mg/kg/day.
- Follow-up ranged from 7 to 13 months to monitor for recurrence.
Main Results:
- Six out of twelve patients showed no signs of recurrence after follow-up.
- Five patients experienced culture-confirmed treatment failure, primarily due to methicillin-resistant Staphylococcus aureus (MRSA).
- Treatment failure occurred both during therapy and post-therapy, with retained hardware being a potential factor.
Conclusions:
- The efficacy of daptomycin 4 mg/kg/day for PJI is uncertain, particularly in cases with retained hardware.
- In vitro susceptibility may not accurately predict clinical success.
- Further research is required to explore higher daptomycin dosages and understand treatment failures.
Related Concept Videos
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:28Antimicrobial Effectiveness
01:18Endocarditis III: Medical Management
01:25Clinical Significance of Antibiotic Resistance
01:29Staphylococcal Skin Infections